Concepts (255)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Repair | 14 | 2022 | 198 | 3.690 |
Why?
|
| Breast Neoplasms | 16 | 2022 | 1723 | 1.670 |
Why?
|
| Skin Neoplasms | 4 | 2011 | 178 | 0.900 |
Why?
|
| DNA, Neoplasm | 2 | 2021 | 92 | 0.820 |
Why?
|
| DNA Methylation | 4 | 2024 | 403 | 0.760 |
Why?
|
| Lymphocytes | 2 | 2020 | 124 | 0.680 |
Why?
|
| Overweight | 1 | 2022 | 249 | 0.640 |
Why?
|
| Vitamin D | 1 | 2020 | 196 | 0.570 |
Why?
|
| DNA Damage | 3 | 2012 | 356 | 0.560 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2011 | 186 | 0.550 |
Why?
|
| Case-Control Studies | 10 | 2018 | 1285 | 0.550 |
Why?
|
| MicroRNAs | 2 | 2023 | 518 | 0.450 |
Why?
|
| Receptors, Estrogen | 1 | 2016 | 183 | 0.440 |
Why?
|
| Aged | 13 | 2024 | 8214 | 0.410 |
Why?
|
| Epigenesis, Genetic | 4 | 2024 | 291 | 0.410 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2024 | 968 | 0.410 |
Why?
|
| Gene Expression | 1 | 2016 | 701 | 0.390 |
Why?
|
| Middle Aged | 16 | 2024 | 12222 | 0.390 |
Why?
|
| BRCA2 Protein | 4 | 2019 | 50 | 0.380 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 2 | 2013 | 4 | 0.380 |
Why?
|
| Neoplasm Staging | 4 | 2021 | 374 | 0.370 |
Why?
|
| Fanconi Anemia | 1 | 2011 | 8 | 0.350 |
Why?
|
| Humans | 36 | 2024 | 43102 | 0.350 |
Why?
|
| Adult | 13 | 2022 | 13872 | 0.350 |
Why?
|
| Female | 22 | 2022 | 24698 | 0.340 |
Why?
|
| Risk Factors | 7 | 2022 | 3994 | 0.320 |
Why?
|
| Melanoma | 1 | 2011 | 110 | 0.320 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 75 | 0.300 |
Why?
|
| Ultraviolet Rays | 2 | 2011 | 118 | 0.300 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 1092 | 0.290 |
Why?
|
| Up-Regulation | 1 | 2011 | 536 | 0.290 |
Why?
|
| Puerto Rico | 10 | 2021 | 1413 | 0.280 |
Why?
|
| Organometallic Compounds | 4 | 2010 | 71 | 0.280 |
Why?
|
| Genes, p53 | 1 | 2007 | 27 | 0.270 |
Why?
|
| Antineoplastic Agents | 6 | 2014 | 1019 | 0.270 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 146 | 0.260 |
Why?
|
| BRCA1 Protein | 3 | 2019 | 58 | 0.240 |
Why?
|
| Logistic Models | 3 | 2016 | 1009 | 0.220 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2004 | 31 | 0.210 |
Why?
|
| Ferrous Compounds | 2 | 2014 | 22 | 0.200 |
Why?
|
| Genetic Variation | 2 | 2018 | 430 | 0.190 |
Why?
|
| Oxocins | 1 | 2002 | 3 | 0.180 |
Why?
|
| Ciguatera Poisoning | 1 | 2002 | 6 | 0.180 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 423 | 0.180 |
Why?
|
| Foodborne Diseases | 1 | 2002 | 23 | 0.180 |
Why?
|
| Acute Disease | 1 | 2002 | 155 | 0.180 |
Why?
|
| Biological Clocks | 1 | 2021 | 52 | 0.180 |
Why?
|
| Norepinephrine | 1 | 2020 | 97 | 0.160 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2020 | 40 | 0.160 |
Why?
|
| Oncogenes | 1 | 2019 | 44 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 734 | 0.150 |
Why?
|
| Keloid | 1 | 2019 | 3 | 0.150 |
Why?
|
| Triamcinolone Acetonide | 1 | 2019 | 3 | 0.150 |
Why?
|
| Neuromuscular Agents | 1 | 2019 | 5 | 0.150 |
Why?
|
| Aged, 80 and over | 4 | 2014 | 2853 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 2019 | 91 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2022 | 925 | 0.140 |
Why?
|
| Genes, BRCA2 | 1 | 2018 | 12 | 0.140 |
Why?
|
| CpG Islands | 3 | 2024 | 109 | 0.140 |
Why?
|
| Ovarian Neoplasms | 2 | 2020 | 415 | 0.140 |
Why?
|
| Male | 13 | 2024 | 23409 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 490 | 0.120 |
Why?
|
| Young Adult | 3 | 2019 | 5080 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 2016 | 92 | 0.120 |
Why?
|
| Subcellular Fractions | 1 | 2005 | 77 | 0.110 |
Why?
|
| Genetic Testing | 1 | 2015 | 91 | 0.110 |
Why?
|
| Photosensitizing Agents | 1 | 2005 | 56 | 0.110 |
Why?
|
| Porphyrins | 1 | 2005 | 57 | 0.110 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 561 | 0.110 |
Why?
|
| Obesity | 1 | 2022 | 1151 | 0.110 |
Why?
|
| Nerve Growth Factors | 1 | 2014 | 34 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 182 | 0.100 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.100 |
Why?
|
| Pilot Projects | 3 | 2021 | 760 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2014 | 50 | 0.100 |
Why?
|
| DNA Repair Enzymes | 1 | 2013 | 22 | 0.100 |
Why?
|
| Minority Health | 1 | 2013 | 95 | 0.100 |
Why?
|
| Phenotype | 1 | 2016 | 780 | 0.100 |
Why?
|
| ROC Curve | 1 | 2012 | 159 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2012 | 150 | 0.090 |
Why?
|
| Ergocalciferols | 1 | 2011 | 6 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 532 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 526 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group C Protein | 1 | 2011 | 1 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group L Protein | 1 | 2011 | 1 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group D2 Protein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2011 | 6 | 0.090 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 611 | 0.080 |
Why?
|
| Apoproteins | 2 | 2008 | 16 | 0.080 |
Why?
|
| Societies, Scientific | 1 | 2010 | 9 | 0.080 |
Why?
|
| Transferrin | 2 | 2008 | 38 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 310 | 0.080 |
Why?
|
| Estrogens | 1 | 2011 | 203 | 0.080 |
Why?
|
| Mutagens | 1 | 2010 | 74 | 0.080 |
Why?
|
| Steroids | 1 | 2010 | 45 | 0.080 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2010 | 55 | 0.080 |
Why?
|
| Molybdenum | 1 | 2009 | 22 | 0.080 |
Why?
|
| Chelating Agents | 1 | 2009 | 52 | 0.070 |
Why?
|
| Colonic Neoplasms | 2 | 2011 | 223 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2009 | 59 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 1081 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 863 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 590 | 0.070 |
Why?
|
| Cell Line, Tumor | 5 | 2020 | 2676 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 706 | 0.070 |
Why?
|
| Epinephrine | 2 | 2020 | 36 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2013 | 587 | 0.070 |
Why?
|
| Age of Onset | 1 | 2007 | 114 | 0.070 |
Why?
|
| Titanium | 1 | 2008 | 48 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2009 | 1124 | 0.060 |
Why?
|
| Health Status Disparities | 1 | 2013 | 719 | 0.060 |
Why?
|
| Models, Molecular | 3 | 2019 | 876 | 0.060 |
Why?
|
| Luciferases | 2 | 2004 | 71 | 0.060 |
Why?
|
| Time Factors | 4 | 2007 | 1857 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2012 | 863 | 0.060 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2004 | 39 | 0.060 |
Why?
|
| Epidemiologic Studies | 1 | 2004 | 33 | 0.060 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2003 | 14 | 0.050 |
Why?
|
| Genetics, Population | 2 | 2015 | 121 | 0.050 |
Why?
|
| Latin America | 2 | 2015 | 55 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 224 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 249 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2009 | 1455 | 0.050 |
Why?
|
| Ligands | 3 | 2009 | 388 | 0.050 |
Why?
|
| Neoplasms | 1 | 2013 | 1377 | 0.050 |
Why?
|
| Copper Sulfate | 1 | 2002 | 5 | 0.050 |
Why?
|
| Ciguatoxins | 1 | 2002 | 3 | 0.050 |
Why?
|
| Marine Toxins | 1 | 2002 | 17 | 0.050 |
Why?
|
| Tropical Climate | 1 | 2002 | 23 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2012 | 2544 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 74 | 0.040 |
Why?
|
| Argentina | 2 | 2012 | 14 | 0.040 |
Why?
|
| Biological Assay | 1 | 2002 | 63 | 0.040 |
Why?
|
| Neurotoxins | 1 | 2002 | 57 | 0.040 |
Why?
|
| Incidence | 1 | 2004 | 1078 | 0.040 |
Why?
|
| Gastrointestinal Diseases | 1 | 2002 | 51 | 0.040 |
Why?
|
| Structure-Activity Relationship | 2 | 2014 | 506 | 0.040 |
Why?
|
| DNA Glycosylases | 1 | 2019 | 17 | 0.040 |
Why?
|
| Genotype | 2 | 2013 | 800 | 0.040 |
Why?
|
| Cisplatin | 1 | 2020 | 98 | 0.040 |
Why?
|
| Point Mutation | 1 | 2019 | 98 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2019 | 91 | 0.040 |
Why?
|
| Pruritus | 1 | 2019 | 4 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 11 | 0.040 |
Why?
|
| Mutation | 2 | 2015 | 1177 | 0.040 |
Why?
|
| Molecular Conformation | 2 | 2010 | 155 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 197 | 0.040 |
Why?
|
| Spectrum Analysis | 2 | 2010 | 61 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 234 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2019 | 317 | 0.030 |
Why?
|
| Infant | 1 | 2002 | 1175 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 667 | 0.030 |
Why?
|
| Introns | 1 | 2018 | 79 | 0.030 |
Why?
|
| Animals | 7 | 2010 | 16992 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2002 | 1546 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 704 | 0.030 |
Why?
|
| Hexanols | 1 | 1975 | 2 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1975 | 29 | 0.030 |
Why?
|
| Acetylcholinesterase | 1 | 1975 | 56 | 0.030 |
Why?
|
| Pain | 1 | 2019 | 290 | 0.030 |
Why?
|
| Caribbean Region | 1 | 2015 | 79 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1975 | 54 | 0.030 |
Why?
|
| Aminoacridines | 1 | 2005 | 1 | 0.030 |
Why?
|
| Acridine Orange | 1 | 2005 | 2 | 0.030 |
Why?
|
| Carbocyanines | 1 | 2005 | 14 | 0.030 |
Why?
|
| Cardiolipins | 1 | 2005 | 12 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 206 | 0.030 |
Why?
|
| Choline | 1 | 1975 | 61 | 0.030 |
Why?
|
| Micronucleus Tests | 1 | 2014 | 16 | 0.030 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2005 | 56 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2005 | 107 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1975 | 206 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2005 | 108 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2019 | 1604 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 1975 | 182 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 64 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2013 | 51 | 0.030 |
Why?
|
| Child | 1 | 2002 | 3443 | 0.030 |
Why?
|
| Community Networks | 1 | 2013 | 107 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 178 | 0.020 |
Why?
|
| Heterozygote | 1 | 2012 | 110 | 0.020 |
Why?
|
| Protein Binding | 2 | 2011 | 1082 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 455 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 199 | 0.020 |
Why?
|
| Adolescent | 2 | 2002 | 6081 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2012 | 110 | 0.020 |
Why?
|
| Mitochondria | 1 | 2005 | 523 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2012 | 145 | 0.020 |
Why?
|
| Estrogen Receptor alpha | 1 | 2011 | 121 | 0.020 |
Why?
|
| Oxygen | 2 | 2009 | 218 | 0.020 |
Why?
|
| Brazil | 1 | 2010 | 84 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 861 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2010 | 79 | 0.020 |
Why?
|
| Titrimetry | 1 | 2009 | 8 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2009 | 63 | 0.020 |
Why?
|
| Environment | 1 | 2010 | 149 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 1234 | 0.020 |
Why?
|
| Electrochemical Techniques | 1 | 2009 | 32 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 139 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2009 | 140 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 2008 | 36 | 0.020 |
Why?
|
| HT29 Cells | 1 | 2008 | 60 | 0.020 |
Why?
|
| Solutions | 1 | 2008 | 65 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2008 | 104 | 0.020 |
Why?
|
| Pregnancy | 1 | 2013 | 1772 | 0.020 |
Why?
|
| Rats | 4 | 1975 | 3735 | 0.020 |
Why?
|
| Thiazoles | 1 | 2008 | 76 | 0.020 |
Why?
|
| Drug Stability | 1 | 2008 | 129 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2009 | 570 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 97 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2008 | 301 | 0.020 |
Why?
|
| Tetanus | 1 | 1976 | 3 | 0.020 |
Why?
|
| Methyltyrosines | 1 | 1975 | 1 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 204 | 0.020 |
Why?
|
| Trypanosoma | 1 | 1975 | 8 | 0.020 |
Why?
|
| Adrenalectomy | 1 | 1975 | 23 | 0.010 |
Why?
|
| Cell Survival | 1 | 2009 | 945 | 0.010 |
Why?
|
| Digitoxin | 1 | 1975 | 7 | 0.010 |
Why?
|
| Respiration | 1 | 1976 | 56 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 1976 | 86 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 75 | 0.010 |
Why?
|
| United States | 1 | 2015 | 5205 | 0.010 |
Why?
|
| Corpus Striatum | 1 | 1975 | 121 | 0.010 |
Why?
|
| Dopamine | 1 | 1975 | 275 | 0.010 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2002 | 157 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 311 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 508 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1976 | 388 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1975 | 52 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1975 | 2 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 1975 | 9 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 1975 | 54 | 0.010 |
Why?
|
| Hexokinase | 1 | 1975 | 10 | 0.010 |
Why?
|
| Propranolol | 1 | 1975 | 18 | 0.010 |
Why?
|
| Mathematics | 1 | 1975 | 57 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 1975 | 110 | 0.010 |
Why?
|
| Phosphorus | 1 | 1975 | 65 | 0.010 |
Why?
|
| Kinetics | 1 | 1975 | 695 | 0.010 |
Why?
|
| Binding Sites | 1 | 1975 | 671 | 0.010 |
Why?
|
| Partial Pressure | 1 | 1976 | 9 | 0.000 |
Why?
|
| Benserazide | 1 | 1975 | 1 | 0.000 |
Why?
|
| Brocresine | 1 | 1975 | 1 | 0.000 |
Why?
|
| Liver Glycogen | 1 | 1975 | 1 | 0.000 |
Why?
|
| p-Hydroxyamphetamine | 1 | 1975 | 1 | 0.000 |
Why?
|
| Homovanillic Acid | 1 | 1975 | 10 | 0.000 |
Why?
|
| 3,4-Dihydroxyphenylacetic Acid | 1 | 1975 | 27 | 0.000 |
Why?
|
| Biological Transport, Active | 1 | 1975 | 27 | 0.000 |
Why?
|
| Blood | 1 | 1976 | 37 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 4 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 12 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 39 | 0.000 |
Why?
|
| NADP | 1 | 1975 | 37 | 0.000 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 1975 | 92 | 0.000 |
Why?
|
| Tyrosine | 1 | 1975 | 120 | 0.000 |
Why?
|
| Glucose | 1 | 1975 | 244 | 0.000 |
Why?
|